secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001628280-21-015854
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q2 2021 revenue $6.6M, 415 LUPKYNIS PSFs, guides FY revenue $40-50M
---------------------------------------------------------------------------

- Net revenue $6.6M (624% growth over Q1 2021); net loss $47.0M ($0.37/share) vs $26.5M loss in Q2 2020.
- Received 415 LUPKYNIS patient start forms in Q2, over 800 YTD; >50% converted to therapy.
- Cash and investments $323.7M; 2021 LUPKYNIS net revenue guidance $40-50M.
- Otsuka filed MAA in EU for voclosporin; Aurinia eligible for up to $30M milestones plus royalties.
- Appointed Dr. Brinda Balakrishnan to Board; Lancet published AURORA-1 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828021015854/0001628280-21-015854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828021015854/auph-20210805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-015854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer